Trial Profile
Phase IIb primary vaccination study to evaluate non-inferiority and persistence of the immune response of GSK Biologicals MenACWY conjugate vaccine (intramuscularly) vs Mencevax ACWY (subcutaneously) to healthy subjects (11-55 Years of age).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Meningococcal vaccine groups A C Y W-135 polysaccharide
- Indications Meningococcal infections
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 02 Aug 2012 Actual end date (1 May 2012) added as reported by ClinicalTrials.gov.
- 02 Aug 2012 Actual end date (1 May 2012) added as reported by ClinicalTrials.gov.
- 02 Aug 2012 Actual end date (1 May 2012) added as reported by ClinicalTrials.gov.